These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32957634)

  • 1. Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
    Yoon HR; Balupuri A; Choi KE; Kang NS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.
    Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.
    Meine R; Becker W; Falke H; Preu L; Loaëc N; Meijer L; Kunick C
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29364148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
    Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
    J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
    Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
    J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
    Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
    Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
    Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
    Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
    Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
    Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation, regulation, and inhibition of DYRK1A.
    Becker W; Sippl W
    FEBS J; 2011 Jan; 278(2):246-56. PubMed ID: 21126318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of the kinase DYRK1A by targeting its folding process.
    Kii I; Sumida Y; Goto T; Sonamoto R; Okuno Y; Yoshida S; Kato-Sumida T; Koike Y; Abe M; Nonaka Y; Ikura T; Ito N; Shibuya H; Hosoya T; Hagiwara M
    Nat Commun; 2016 Apr; 7():11391. PubMed ID: 27102360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations.
    Li JJ; Tian YL; Zhai HL; Lv M; Zhang XY
    Proteins; 2016 Aug; 84(8):1108-23. PubMed ID: 27119584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Lechner C; Flaßhoff M; Falke H; Preu L; Loaëc N; Meijer L; Knapp S; Chaikuad A; Kunick C
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31766108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-step virtual screening to develop selective DYRK1A inhibitors.
    Koyama T; Yamaotsu N; Nakagome I; Ozawa SI; Yoshida T; Hayakawa D; Hirono S
    J Mol Graph Model; 2017 Mar; 72():229-239. PubMed ID: 28129593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.
    Huizar FJ; Hill HM; Bacher EP; Eckert KE; Gulotty EM; Rodriguez KX; Tucker ZD; Banerjee M; Liu H; Wiest O; Zartman J; Ashfeld BL
    ChemMedChem; 2022 Feb; 17(4):e202100512. PubMed ID: 34994084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors.
    Pan Y; Wang Y; Bryant SH
    J Chem Inf Model; 2013 Apr; 53(4):938-47. PubMed ID: 23496085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
    Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J
    Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ.
    Sonamoto R; Kii I; Koike Y; Sumida Y; Kato-Sumida T; Okuno Y; Hosoya T; Hagiwara M
    Sci Rep; 2015 Aug; 5():12728. PubMed ID: 26234946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
    Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.